.....as the company continues "its growth trajectory". Stuff me - measured how??
Emailed the co 2 days ago (after having discussed frustrations, partic re less than adequate explanations for 1) what happened and 2) details of new sales approach - with PR man).
Key points -
- SHC: a distinct lack of ANY detail as to why this path led nowhere has left a cloud hanging over PIQ ie shareholders (current and potential) have been left to speculate whether a key factor in the breakdown was a problem (or problems) with Promarker D itself. It is manifestly inadequate to simply then propose an alternative strategy and state all should be good in another 8-12 months. If anyone thinks otherwise, look at the share price !!
If the Board – with the advantage of hindsight – made the wrong call (but presumably the right one based on the information available at the time) – own it and explain what’s going to happen as a result.
- The DTC approach: how will this work in (some) detail? Why will it be better that using sales reps via an established distributor? If it is better, why are apparently relying on sales agents in Europe (for apparently little or no success, or even progress, so far)?
- ‘Down the Track’: Explain how will the new approach(es) benefit the next generation of tests ie Endo etc
IMO, what is required is a well constructed letter to shareholders addressing the above and the logical conclusion of which will be significant sales in due course (as against the oft stated and stand alone “Share Price Catalysts: Generate sales revenue for PromarkerD in the USA” ).
The overriding aim is to instill confidence in the management of the company (including, if applicable, a statement to the effect “the Board acknowledges the Company needs the services of…..to achieve sales revenues the technology should be achieving”).
I’m sure many shareholders are as frustrated as I with the lack of sales (again, refer the current share price if anyone thinks such frustration unreasonable). Noone disputes patience is required with significant commercial ventures but quality communication is essential in the meantime.
I desperately want PIQ to do well. More light needs to be thrown on the current marketing moves so that SH can decide if PIQ on the right path or the light bulb needs to be replaced with a blow torch .
- Forums
- ASX - By Stock
- PIQ
- Ann: Board renewal update
PIQ
proteomics international laboratories ltd
Add to My Watchlist
0.00%
!
39.5¢

Ann: Board renewal update, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
39.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.65M |
Open | High | Low | Value | Volume |
39.0¢ | 40.0¢ | 38.0¢ | $98.01K | 252.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9722 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 44999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9722 | 0.380 |
1 | 1400 | 0.375 |
6 | 97160 | 0.370 |
1 | 10000 | 0.365 |
4 | 13174 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 44999 | 1 |
0.400 | 14573 | 2 |
0.410 | 100000 | 1 |
0.420 | 10000 | 1 |
0.430 | 20000 | 1 |
Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online